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Abstract
Background: Colorectal cancer is a common cancer all over the world. Aberrations in the cell
cycle checkpoints have been shown to be of prognostic significance in colorectal cancer.
Methods: The expression of cyclin D1, cyclin A, histone H3 and Ki-67 was examined in 60 colorectal
cancer cases for co-regulation and impact on overall survival using immunohistochemistry,
southern blot and in situ hybridization techniques. Immunoreactivity was evaluated semi
quantitatively by determining the staining index of the studied proteins.
Results: There was a significant correlation between cyclin D1 gene amplification and protein
overexpression (concordance = 63.6%) and between Ki-67 and the other studied proteins. The
staining index for Ki-67, cyclin A and D1 was higher in large, poorly differentiated tumors. The
staining index of cyclin D1 was significantly higher in cases with deeply invasive tumors and nodal
metastasis. Overexpression of cyclin A and D1 and amplification of cyclin D1 were associated with
reduced overall survival. Multivariate analysis shows that cyclin D1 and A are two independent
prognostic factors in colorectal cancer patients.
Conclusions: Loss of cell cycle checkpoints control is common in colorectal cancer. Cyclin A and
D1 are superior independent indicators of poor prognosis in colorectal cancer patients. Therefore,
they may help in predicting the clinical outcome of those patients on an individual basis and could
be considered important therapeutic targets.
Background
Colorectal cancer (CRC) is the third most common cancer
in Western countries [1]. In Egypt, CRC has unique char-
acteristics that differ from that reported in other countries
of the western society. It was estimated that 35.6% of the
Egyptian CRC cases are below 40 years of age and patients
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usually present with advanced stage, high grade tumors
that carry more mutations [2]. This uniquely high propor-
tion of early-onset CRC, the early and continuous expo-
sure to hazardous environmental agents, the different
mutational spectrum and the prevalent consanguinity in
Egypt justify further studies [3]. It was proved that most
cancers result from accumulation of genetic alterations
involving certain groups of genes, the majority of which
are cell cycle regulators that either stimulate or inhibit cell
cycle progression [1]. Cell proliferation allows orderly
progression through the cell cycle, which is governed by a
number of proteins including cyclins and cyclin dependent
kinases [4,5]. The cyclins belong to a superfamily of genes
whose products complex with various cyclin-dependent
kinases (cdks) to regulate transitions through key check-
points of the cell cycle [6]. Abnormalities of several cyclins
have been reported in different tumor types, implicating,
in particular, cyclin A, cyclin E and cyclin D [6,7].
Cyclin D1 is a G1 cyclin that regulates the transition from
G1 to S phase since its peak level and maximum activity
are reached during the G1 phase of the cell cycle. Whereas
cyclin A is regarded a regulator of the transition to mitosis
since it reaches its maximum level during the S and G2
phases [8]. The mechanisms likely to activate the onco-
genic properties of the cyclins include chromosomal trans-
locations, gene amplification and aberrant protein
overexpression [7,9].
Several studies have shown that, histone H3 mRNA expres-
sion can be used to identify the S phase fraction (SPF)
through the in situ hybridization (ISH) technique [10,11].
The level of histone H3 mRNA reaches its peak during the
S phase and then drops rapidly at the G2 phase [12].
In face of the increasing incidence of CRC and its peculiar
pattern in the Egyptian population, the present study was
conducted to assess the role of Ki-67  (pan-cell cycle
marker), cyclin D1 (G1 phase marker), histone H3 mRNA
(S phase marker), cyclin A (S to G2 phase marker) in CRC.
The expression level of these markers was correlated to the
clinicopathologic features and the overall survival of
patients.
Table 1: Clinicopathological features of patients in relation to the staining index (SI) of Ki-67, cyclin D1, cyclin A, histone H3
SI (mean + SD)
Variables No. of cases Ki-67 Cyclin DI Cyclin A Histone H3
Sex
Male 36 18.0 ± 6.4 6.7 ± 4.3 12.7 ± 5.7 10.7 ± 5.3
Female 24 20.1 ± 5.8 8.8 ± 8.4 10.0 ± 6.0 10.7 ± 5.4
Age (years)
≥50 41 11.7 ± 6.0* 5.6 ± 5.2 10.0 ± 5.3 6.0 ± 5.0*
<50 19 23.8 ± 5.6 7.7 ± 6.8 13.6 ± 5.7 22.0 ± 5.2
Tumor size (cm)
<5.0 33 12.2 ± 6.3* 5.3 ± 3.8* 11.5 ± 6.1* 10.3 ± 4.9*
≥5.0 27 30.1 ± 6.2 22.8 ± 7.2 28.6 ± 5.6 24.0 ± 5.6
Histology
Normal 20 3.5 ± 2.0* 0.6 ± 0.2* 2.3 ± 1.1* 2.2 ± 0.9
Carcinoma 60 30.3 ± 6.2 24.9 ± 6.3 27.2 ± 5.8 10.7 ± 5.3
GI 15 11.7 ± 6.2 6.6 ± 4.0 10.0 ± 5.4 11.4 ± 4.9
GII 21 11.8 ± 5.6 8.9 ± 3.6 12.3 ± 6.5 7.8 ± 5.4
GIII 24 30.0 ± 4.3 22.0 ± 8.1 27.0 ± 4.9 11.5 ± 5.4
Lymph node
Negative 33 19.5 ± 7.0 5.4 ± 5.3* 11.9 ± 6.5 12.3 ± 5.5
Positive 27 21.3 ± 4.9 20.6 ± 6.9 12.5 ± 5.0 14.2 ± 5.0
Depth of invasion
m, sm 17 20.7 ± 6.7 3.1 ± 3.1* 11.9 ± 7.2 10.4 ± 5.1
beyond sm 43 21.9 ± 6.2 12.4 ± 6.5 12.2 ± 5.6 10.7 ± 5.4
Stage
I 6 20.6 ± 6.7 5.7 ± 6.9 24.2 ± 6.9 11.1 ± 5.3
II 27 20.8 ± 6.9 5.3 ± 4.3 24.6 ± 6.0 10.4 ± 5.7
III 12 22.0 ± 5.4 7.7 ± 6.0 27.1 ± 5.2 10.4 ± 4.9
IV 15 24.7 ± 6.1 11.3 ± 9.6 27.5 ± 5.5 12.3 ± 6.2
* p. value < 0.05 (significant)BMC Gastroenterology 2004, 4:22 http://www.biomedcentral.com/1471-230X/4/22
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Methods
Tissue samples
Paraffin-embedded tumor tissues were obtained from 60
CRC patients (47 colon and 13 rectal carcinomas) that
were diagnosed and treated at the National Cancer Insti-
tute, Cairo, Egypt during the period from January, 1997 to
June, 2002. Clinicopathological data of the studied cases
are illustrated in table 1. None of the patients received any
chemotherapy or irradiation prior to surgery. Histological
diagnosis of all cases was done by 2 independent pathol-
ogists according to the WHO Histological Classification.
Tumors were staged according to the TNM staging system
[13]. The depth of tumor invasion was classified as inva-
sion of the mucosa including muscularis mucosa (m),
invasion of the submucosa (sm), or invasion beyond the
submucosa [8]. Normal colonic tissues were obtained
from autopsy specimens (n = 20) and were used as a con-
trol. The actual survival rate of the patients was calculated
from the date of resection to the date of death.
Immunohistochemistry
Four micron sections of each normal and tumor specimen
were cut onto positive-charged slides; air dried overnight,
de-paraffinized in xylene, hydrated through a series of
graded alcohol and washed in distilled water and 0.01
PBS (pH 7.4). Slides were then processed for IHC as
described by Handa et al. [8]. using the following anti-
bodies: Ki-67 (MIB-1, Dako), cyclin A (6E6; Novocastra,
Newcastle-Upon-Tyne, UK) and cyclin D1 (DCS-6, Dako).
A case of invasive breast cancer was used as a positive con-
trol for Ki-67 and cyclin A whereas a case of mantle cell
lymphoma was used as a control for cyclin D1. Negative
controls were obtained by replacing the primary antibody
by non-immunized rabbit or mouse serum.
Brown nuclear staining was regarded as a positive result
for all studied markers. The proportion of positively-
stained cells and the intensity of staining were scored in
tumor and normal colorectal mucosal sections at medium
power (×200). The degree of positive tumor staining (per-
centage of positive tumor cells in the examined section)
was scored from 1–6 and the staining intensity was scored
from 0–6 according to the pattern of staining in the exam-
ined section. Staining index (SI) was calculated by multi-
plying the cellularity and staining scores as described by
King et al. [14].
In situ hybridization
All tumor samples and 5 normal controls were assessed
for histone H3 mRNA by ISH using the commercially avail-
able 550 base fluorescein-labeled DNA probe (Dako,
Carpinteria, CA) as described by Nagao et al., 1996. This
probe hybridizes to the whole mRNA transcript of the
human histoneH3 gene including the5' and 3' un-trans-
lated regions. Scoring of histone H3 mRNA was performed
as for immunohistochemistry, however, hybridization
signals were detected in the cytoplasm.
Molecular detection of cyclin D1 gene amplification
High molecular weight DNA was extracted from paraffin-
embedded tissues of the tumor and normal colorectal
mucosal samples as previously described [15]. The pro-
portion of neoplastic and normal cells was determined in
each tumor sample by examining hematoxylin and eosin-
stained slides obtained from the edge of the specimen
used for DNA extraction. Tumor samples were evaluated
for amplification of cyclin D1 if more than 75% of the
examined sections were formed of neoplastic cells.
Accordingly, 50 cases were eligible for the analysis. Ten
micrograms of the extracted DNA was digested with
EcoR1. DNA from selected cases was also digested with
BglII and HindIII. Samples were separated on 0.8% agar-
ose gels and transferred to Hybond-N membranes (Amer-
sham Int., Amersham, UK). The membranes were
hybridized with 50% formamide, 5 × SSC, 5 × Denhardt's,
500 µg/ml denatured salmon sperm DNA, 10% dextran
sulphate and 106 cpm/ml of 32P-labeled PRAD-1 probe for
24 h. Membranes were washed with 2 × SSC, 0.1% SDS at
room temperature for 30 min followed by 2 × SSC, 0.1%
SDS at 60°C for 30 min and 0.1 × SSC, 0.1% SDS at 60°C
for 1 h. Filters were autoradiographed using an intensify-
ing screen at -70°C for 24–72 h. After being stripped free
of the PRAD-1 probe, the same blots were hybridized with
32P-labeled B-actin probe to normalize against possible
variations in the loading or transfer of DNA. The autora-
diograms were analyzed using a densitometer. Intensities
of PRAD-1/cyclin D1 were normalized to the β-actin con-
trol bands. The degree of amplification was calculated
from these normalized values. Amplification was consid-
ered when the signal of the tumor band was ≥2-fold the
value of the matched normal mucosa [16].
Statistical analysis
The Mann-Whitney non-parametric test was used to com-
pare the SIs of pairs of subjects whereas the Kruskal-wallis
was used for categorial data. Correlation between indices
was performed using a simple linear regression test. The
Kaplan-Meier method was used to create survival curves
which were analyzed by the log-rank test. The impact of
different variables on survival was determined using the
Cox proportional hazards model. p. values less than 0.05
were considered significant.
Results
The results of IHC are illustrated in figures 1 and 2. In gen-
eral, the staining index (SIs) of all studied markers was
higher in carcinomas than in normal colonic mucosal
samples (p = 0.0001). Normal colorectal mucosa revealed
positive imunostaining for Ki-67 in the lower half of the
crypts only. A heterogeneous staining pattern wasBMC Gastroenterology 2004, 4:22 http://www.biomedcentral.com/1471-230X/4/22
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detected in the neoplastic cells of well and moderately-dif-
ferentiated adenocarcinomas whereas a diffuse homoge-
neous staining pattern was detected in poorly-
differentiated carcinomas. The SI ranged from 10–40.2
(mean: 24.6 ± 6.5).
Immunostaining for cyclin D1 was predominantly nuclear
but cytoplasmic staining was detected in some cases.
However, unless a nuclear staining was also detected,
cases with cytoplasmic staining were considered negative.
Normal colorectal mucosal samples were almost negative
for cyclin D1 whereas 41 out of the 60 (68.3%) CRC cases
were positive. Marked heterogeneity was observed in well-
and moderately-differentiated adenocarcinomas even
within the same tumor. Poorly-differentiated carcinomas
revealed a diffuse staining pattern with more darkly-
stained nuclei. The SI ranged from 0.5–28.6 (mean: 9.3 ±
4.2).
Positive nuclear staining for cyclin A was detected in 80%
(48/60) of CRC cases and in all non-neoplastic control
samples. Positively-stained nuclei were confined to the
lower half of the crypts in normal colonic mucosa and dif-
fusely-dispersed in carcinomas. The SI ranged from 3.3–
30.2 (mean: 15.1 ± 6.6).
Histone H3 mRNA was intensely expressed in the cyto-
plasm of all examined samples either neoplastic or non-
neoplastic. The distribution of histone H3 mRNA was
similar to that of cyclin A and Ki-67 however, the propor-
tion of histone H3 mRNA positive cells was less than that
of Ki-67. The SI ranged from 1.8–24.2 (mean: 12.4 ± 5.3).
The PRAD-1 probe detected 3 EcoRI fragments of 4.0, 2.2
and 2.0 and 1 BglII fragment of 15 Kb. PRAD-1/cyclin D1
gene amplification was detected in 22/50 (44%) cases
analyzed. The degree of amplification was heterogeneous
Normal colonic mucosa showing positive nuclear immunostaining for: (a) cyclin D1, (b) ISH of histone H3 mRNA, (c) Ki-67 and  (d) cyclin A Figure 1
Normal colonic mucosa showing positive nuclear immunostaining for: (a) cyclin D1, (b) ISH of histone H3 mRNA, (c) Ki-67 and 
(d) cyclin ABMC Gastroenterology 2004, 4:22 http://www.biomedcentral.com/1471-230X/4/22
Page 5 of 12
(page number not for citation purposes)
with 2–10 fold increase when compared to normal
mucosal samples (Figure 3). Amplification was confirmed
by other restriction enzymes.
Correlations
There was a significant correlation between cyclin D1 gene
amplification and protein overexpression. Out of the 22
cases that showed amplification 14 showed protein over-
expression (concordance = 63.6%).
Linear regression analysis of SIs revealed a significant cor-
relation between Ki-67 and cyclin D1, cyclin A, histone H3
as well as between the SIs of cyclin A and histone H3 (p =
0.008, 0.0001, and 0.0001 respectively) (Figure 4). There
was a significant relationship between the SI of both Ki-67
A case of well differentiated adenocarcinoma with positive immunostaining for: (a) cyclin D1, (b) histone H3 mRNA, (c) Ki-67,  and (d) cyclin A Figure 2
A case of well differentiated adenocarcinoma with positive immunostaining for: (a) cyclin D1, (b) histone H3 mRNA, (c) Ki-67, 
and (d) cyclin A. Another case of moderately differentiated denocarcinoma with positive immunostaining for: (e) cyclin D1, (f) 
histone H3 mRNA, (g) Ki-67, and (h) cyclin A. A case of poorly differentiated adenocarcinoma with diffuse staining for: (i) cyclin 
D1, (j) ISH of histone H3 mRNA, (k) Ki-67 and (l) cyclin A.BMC Gastroenterology 2004, 4:22 http://www.biomedcentral.com/1471-230X/4/22
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and cyclin A and the degree of differentiation of tumors as
well as the size of the tumor (p < 0.001 and p < 0.01
respectively). In addition, SI of Ki-67 and histone H3 were
higher in patients <50 years than in those ≥50 years (p <
0.05) (table 1).
In addition table 2 shows a significant relationship
between high cyclin D1 SI and large, poorly-differentiated
tumors, carcinomas with positive lymph node metastasis
and deeply-invasive carcinomas (p < 0.05, p < 0.001, p <
0.05 and p < 0.05 respectively). Whereas cyclin D1 gene
amplification was significantly associated with an
advanced disease stage since amplification was detected in
A: Southern blot analysis of normal mucosa (N) and their seven corresponding cases of colonic adenocarcinomas (T1–T7),  cases No. 1, 2, 4, and 5 are poorly differentiated whereas cases No. 3, 6, and 7 are moderately differentiated Figure 3
A: Southern blot analysis of normal mucosa (N) and their seven corresponding cases of colonic adenocarcinomas (T1–T7), 
cases No. 1, 2, 4, and 5 are poorly differentiated whereas cases No. 3, 6, and 7 are moderately differentiated. Genomic DNA 
was digested with BglII, fractionated by electrophoresis in agarose gel, transferred onto membranes and hybridized with PRAD1 
and β-actin. Tumors number 1–6 (Lanes 1–6) show different degrees of PRAD1/cyclin D1 amplification, tumor number 7 (lane 7) 
was not amplified. B: Southern blot analysis of 3 cases of adenocarcinomas (T) and matched normal colonic mucosa (N). 
Genomic DNA was digested with EcoRI, fractionated by electrophoresis in agarose gel, transferred onto membranes and 
hybridized with PRAD1 and β-actin probes for loading control. The identification of the 3 tumors is the same as in Fig. 3A with 
amplification of PRAD1/cyclin D1 in tumors number 4, 5 (Lanes 1, 2) but not 7 (Lane 3).BMC Gastroenterology 2004, 4:22 http://www.biomedcentral.com/1471-230X/4/22
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10/15 (66.7%) of stage IV tumors compared to 12/45
(26.7%) of stage I-III tumors (p = 0.002). Similarly, DNA
amplification was detected in 60.5% (26/43) of the carci-
nomas with extensive local invasion (beyond sm) but
only in 23.5% (4/17) of the carcinomas with limited inva-
sion (m, sm) (p = 0.001). A significant correlation was
also present between cyclin D1 gene amplification and the
presence of lymph node metastasis (p = 0.008) as well as
between the SI of histone H3, the size of the tumor and the
patient's age (p < 0.05, p < 0.001 respectively). The SI was
higher in tumors >5 cm in diameter and in patients <50
years.
Survival analysis
The mean follow-up period for all patients was 30 months
(range: 1–66 months). Eighteen of 60 patients had
already died by the time the study was completed. We
defined the cutoff level for overexpression of each cell
cycle marker at the point that showed the maximum dif-
ference of survival rate between the 2 groups separated by
that point. Cox regression analysis revealed that cyclin A
overexpression (our definition: SI ≥ 10.5), cyclin D1 over-
expression (our definition: SI ≥ 6.1), poorly differentiated
histology, lymph node metastasis, TNM stage, tumor size
and depth of invasion were all significant prognostic var-
iables for survival (Table 3). The Kaplan-Meier survival
curves for the subgroups of patients who are subdivided
according to each marker's status are shown in Figure 5.
Patient with tumors that showed Ki-67  overexpression
(our definition: SI ≥ 11.5) and histone H3 overexpression
(our definition: SI ≥ 8.2) tended to have poor prognosis
but this did not reach a statistically significant level, how-
ever the overall survival was significantly lower in patient
with cyclin A and cyclin D1 overexpression. Cox multivari-
Correlation between the staining intensity of (a) Ki-67 vs. cyclin D1, (b) Ki-67 vs. histone H3, (c) Ki-67 vs. cyclin A and (d) cyclin A  vs. histone H3 mRNA expression Figure 4
Correlation between the staining intensity of (a) Ki-67 vs. cyclin D1, (b) Ki-67 vs. histone H3, (c) Ki-67 vs. cyclin A and (d) cyclin A 
vs. histone H3 mRNA expression.BMC Gastroenterology 2004, 4:22 http://www.biomedcentral.com/1471-230X/4/22
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Table 2: The relation between cyclin D1 overexpression vs cyclin D1 amplification and clinicopathological prognostic markers.
Variables No. of cases Cyclin DI overexpression Cyclin D1 Amplification
Tumor size (cm)
<5.0 33 5.3 ± 3.8* 13/33
≥5.0 27 22.8 ± 7.2 p <0.05 9/27 p <0.236
Histology
GI 15 6.6 ± 4.0 7/15
GII 21 8.9 ± 3.6 8/21
GIII 24 22.0 ± 8.1 p <0.001 7/24 p <0.075
Lymph node
Negative 33 5.4 ± 5.3* 6/33 (18.2%)
Positive 27 20.6 ± 6.9 p <0.05 16/27 (59.3%) p <0.008
Depth of invasion
m, sm 17 3.1 ± 3.1* 4/17 (23.5%)
beyond sm 43 12.4 ± 6.5 p <0.05 26/43 (60.5%) p <0.001
Stage
early 45 5.5 ± 10.1 12/45 (26.7%)
late 15 11.3 ± 9.6 P = 0.175 10/15 (66.7%) p <0.002
Table 3: Uunivariate analysis of the relationship between survival and the tested markers
PredictiveVariables Median Survival HR CI P
Ki-67
<11.5 36
≥11.5 32 1.826 0.636 – 5.243 0.26
Cyclin D1
<6.1 35
≥6.1 18 7.246 1.007 – 45.150 0.03*
Histone H3
<8.2 35
≥8.2 29 4.639 0.854 – 25.196 0.07
Cyclin A
<10.5 35
≥10.5 15 7.820 1.017 – 60.122 0.02*
Histological grade
Low 38
High 10 7.331 2.696 – 19.940 0.0001*
Lymph node
Negative 38
Positive 15 6.826 1.973 – 23.621 0.002*
Stage
I, II, III 38
IV 12 6.378 1.842 – 22.083 0.001*
Tumor size (cm)
<5.0 35
≥5.0 13 4.835 1.386 – 16.868 0.01*
Depth of invasion
T1, T2 36
T3, T4 20 7.759 1.024 – 58.789 0.04*
Age (years)
<50 38
≥50 28 2.802 0.988 – 7.943 0.0526
Sex
Male 38
Female 36 0.696 00.274 – 1.766 0.4449
* p. value < 0.05 (significant)
HR: Hazard Ratio
CI: 95% confidence IntervalBMC Gastroenterology 2004, 4:22 http://www.biomedcentral.com/1471-230X/4/22
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ate regression analysis revealed that lymph node metasta-
sis,  cyclin A and  cyclin D1 overexpression were
independent negative prognostic factors after adjustment
for the depth of tumor invasion, age and sex of the patient
(Table 4).
Discussion
The proliferative activity of CRC cells has been investi-
gated in several studies either by immunohistochemical
determination of cell proliferation index using antibodies
to some types of cyclins or by flowcytometric determina-
tion of the SPF of the cell cycle [8]. Although Leach et al.
[17] did not find cyclin D1 gene amplification in a panel
of 47 CRC cell lines; its protein was overexpressed in
about 30% of CRC cases that were included in the studies
of Bartakova et al. [6] and Arber et al. [18]. In the former
study [6]cyclin D1 was aberrantly accumulated in a
significant subset of human CRC cases and the cell lines
derived from these cases were dependent on cyclin in their
cell cycle progression. In the second study [18], overex-
pression of cyclin D1 was detected in 30% of adenomatous
polyps indicating that overexpression is a relatively early
event in colon carcinogenesis which is possibly responsi-
ble for the pathological changes in the mucosa preceding
neoplastic transformation. More recently, Holland et al.
[19], Pasz-Walczak et al. [20] and Utsunomiya et al. [21]
reported up-regulation of cyclin D1 in 58.7%, 100% and
43% of their studied cases respectively.
Kaplan-Meier survival curves for colorectal carcinoma Figure 5
Kaplan-Meier survival curves for colorectal carcinoma. Overall survival is significantly lower in patients with (a) cyclin A and (b) 
cyclin D1 overexpression. Patients with high SI for histone H3 mRNA have poorer prognosis but this was not statistically signif-
icant (c). No significant difference was present between patients with high Ki-67 SI and those with low Ki-67 SI (d).BMC Gastroenterology 2004, 4:22 http://www.biomedcentral.com/1471-230X/4/22
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In the present study, up-regulation of cyclin D1 was
detected in 68.3% of the cases. The SI was significantly
higher in carcinomas than in normal colorectal mucosa
and in poorly-differentiated adenocarcinomas it was
approximately twice that of other histological types.
Amplification and/or overexpression of cyclin D1 signifi-
cantly correlated with deeply invasive tumors and positive
lymph node metastasis. Our results in this regards are con-
sistent with previous studies [8,22]. In 2001, Holland et
al. [19]. demonstrated that deregulation of cyclin D1 and
p21waf proteins are important in colorectal tumorigenesis
and have implications for patient prognosis. Similarly
McKay et al. [23] found that cyclin D1 was the only protein
in their panel (cyclin D1, p53, p16, Rb-1, PCNA and p27)
that correlated with improved outcome in CRC patients.
However, few studies failed to detect any correlation
between  cyclin D1 overexpression and the
clinicopathological factors in CRC [6,18]. This contro-
versy in results could partially be explained by the differ-
ence in the sampling of studied cases. The present study
included 24 cases of poorly differentiated adenocarci-
noma, which is not common in other studies of CRC in
western countries. This was possible because the majority
of CRC cases diagnosed in Egypt are of high histological
grade [3]. The correlation between cyclin D1 overexpres-
sion and the high histological grade was also reported in
other tumor types including non-small cell lung
carcinomas [24] and squamous cell carcinomas of the lar-
ynx [16]. Another possible explanation for the observed
controversy in the results of different studies is the detec-
tion method used.
In the present work, overexpression of cyclin D1 was more
common than gene amplification of the PRAD-1/cyclin D1
gene with a 63.6% concordance. This was similarly
reported by Bartakova et al. [6] who mentioned that there
is a subset of CRC cases in which cyclin D1 is overex-
pressed without PRAD-1/cyclin D1 gene amplification.
Consistent with this hypothesis are reports of elevated cyc-
lin D1 mRNA levels and immunohistochemically detecta-
ble accumulation of the protein in over one third of breast
cancer cases at a frequency significantly higher than that
deduced from DNA amplification studies [9,25]. These
data imply that mechanisms other than gene
amplification can also lead to deregulation and accumu-
lation of cyclin D1 in solid tumors.
So far, several studies were done to reveal the prognostic
significance of cyclin D1 overexpression in various carci-
nomas, including CRC [22]. However, these studies
yielded conflicting results which could be attributed to
organ heterogeneity. In our study, patients with tumors
that exhibited cyclin D1 overexpression tended to have
poor prognosis.
It was reported that, patients with cyclin A positive carci-
nomas had significantly shorter median survival times.
Handa et al. [8] were able to detect cyclin A overexpression
in 77% of their CRC cases. They also demonstrated that,
cylcin A could be used as a prognostic factor of CRC. More
recently, Habermann et al. [26] studied cases of ulcerative
colitis with and without an associated adenocarcinoma
for the presence of cyclin A overexpression. They found
that, cyclin A overexpression was higher in cases of ulcera-
tive colitis with adenocarcinomas than in those without
adenocarcinomas. Consequently, they concluded that,
cyclin A could be used for monitoring ulcerative colitis
patients and for the early detection of an emerging carci-
noma in this high risk group of patients.
In our study, cyclin A was detected in 80% of the patients
and Cox regression analysis showed that it could be used
as a prognostic marker in CRC in addition to cyclin D1.
It would have been useful if we assessed the expression
level of cyclin A by another technique (DNA
amplification). This would have added more information
regarding the gene status on one hand and confirmed the
results of IHC on the other hand. Unfortunately, this was
not possible because in most of the cases included in the
present work, the extracted DNA was not sufficient to
study cyclin amplification after the assessment of cyclin D1.
In 1996, Nagao et al. [11] reported that histone H3 labe-
ling index significantly correlated with ki-67 immunos-
taining and was high in poorly differentiated human
hepatocellular carcinoma. This was similarly reported in
the present work since we found a significant correlation
between the SI of histone H3 and  Ki-67. However, no
Table 4: Multivariate analysis ofthe relationship between survival 
and thetested markers
PredictiveVariables HR CI P
Cyclin D1 10.864 1.055 – 86.250 0.03*
(baseline < 6.1) - - -
Cyclin A 13.886 1.012 – 190.579 0.0490*
(baseline < 10.5) - - -
Positive Lymph node 
metastasis
3.921 1.057 – 14.472 0.0410*
Stage IV 3.411 1.048 – 12.083 0.03*
Depth of invasion
T3, T4 5.408 0.449 – 65.080 0.1836
Age (years)
≥50 1.996 0.678 – 5.878 0.2310
Sex 0.910 0.315 – 2.358 0.8453
p. value < 0.05 (significant)
HR: Hazard Ratio
CI: 95% confidence IntervalBMC Gastroenterology 2004, 4:22 http://www.biomedcentral.com/1471-230X/4/22
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statistically significant correlation was found between his-
tone H3 SI and any of the studied clinicopathological
factors.
Although Ki-67 immunostaining reflects the proliferative
activity of CRC, it has not been recognized as a significant
prognostic factor in this type of tumors [27,28]. However,
Suzuki at al. [29] found a significant correlation between
Ki-67 labeling index and local invasion of CRC. In the
present study there was a significant relationship between
the SI of Ki-67, tumor size and grade. However, Kaplan-
Meier survival curves showed no significant difference in
survival rates between patients with- and without overex-
pression of Ki-67.
Conclusions
Our results demonstrate that cyclin D1, cyclin A, histone H3
and Ki-67 are overexpressed in a subset of CRC, however
only cyclin D1 and cyclin A overexpression correlates with
poor differentiation and tumor progression. This indi-
cates the superiority of cyclin A and cyclin D1 as indicators
of poor prognosis compared to Ki-67  and  histone H3
mRNA in CRC. Cyclin A and D1 could therefore be consid-
ered significant, independent prognostic factors in CRC
patients. These findings are especially important in stage
II patients since 25–30% of those patients have poor prog-
nosis in spite of being node-negative. However, the stand-
ard clinicopathologic prognostic factors can not identify
this subset accurately and therefore; there is a great
demand for more accurate, individually-based, biological
prognostic parameters that help in detecting this high risk
group of patients who can benefit from an adjuvant ther-
apy. If the findings of the present study are confirmed in a
larger study, evaluation of cyclin A and D1 may be applica-
ble to clinical management of CRC, allowing the identifi-
cation of patients with poor prognosis.
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